Antipsychotic Class Warning On Cerebrovascular Events Under FDA Review
FDA is considering class labeling for atypical antipsychotics on an increased risk of cerebrovascular events in elderly dementia patients
FDA is considering class labeling for atypical antipsychotics on an increased risk of cerebrovascular events in elderly dementia patients